C-Path is excited to welcome Avidity Biosciences as a new member of the Duchenne Regulatory Science Consortium (D-RSC). Avidity is pioneering a new class of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics.
They recently announced positive topline data from their clinical program in Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) and remain on track to submit a Biologics License Application (BLA) by the end of the year. Avidity is deeply committed to the Duchenne community and to advancing potential treatments that can have a meaningful impact on the lives of individuals and families affected by this serious rare disease. We thank Avidity Biosciences for their continued partnership and look forward to their involvement and contributions to our collaborative and pre-competitive efforts to advance drug development.
